Skip to main content

Table 4 AS, DHA and MQ final model-predicted secondary pharmacokinetic parameters

From: Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

Derived parameter [median (PI95%)] AS DHA MQ
Cmax 0.52 (0.17, 1.43) nmol/mL 3.9 (1.0, 11.4) nmol/mL 2874 (1099–4994) ng/mLa
tmax (h) 0.52 1.4 (1.0–1.7) 56 (35–62)a
t1/2 40 min 40 (20–81) min 12 (9–24) day
AUC0–24, day 0 (ng/L/h) 0.34 (0.12, 0.93) 3.30 (0.88, 9.30)
AUC0–24, day 2 (ng/L/h) 0.23 (0.08, 0.64) 2.20 (0.60, 6.30)
AUC0–inf (ng/L/h) 650 (251–1619)
  1. Cmax, maximum concentration; tmax, time to achieve Cmax; t1/2, terminal half-life; AUC0–24, day0 and AUC0–24, day2, area under the curve (area under the curve) after the first and third ASMQ intake, respectively; AUC0–inf, AUC to infinite
  2. aTwo patients received only 1 MQ dose and have a tmax < 50 h with a Cmax < 1000 ng/mL